Is Novo Nordisk Still an Attractive Investment?
The market has been enthusiastic about big pharma stocks like Johnson & Johnson and Pfizer so far this year. But shares of Danish drugmaker Novo Nordisk have only climbed a modest 6% year to date. Part of the stock's lackluster performance comes down to the Food and Drug Administration's rejection of its long-acting insulin Tresiba earlier this year. The drug has been launched in some international markets, but failing to get it on the U.S. market this year has been a blow to the company's near-term-revenue growth. Nevertheless, the stock's current valuation and long-term opportunities could be attractive to some investors. In the following video, analysts Simon Erickson and Max Macaluso discuss reasons to be optimistic about Novo Nordisk's long-term prospects.
The Motley Fool's top stock of 2014
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!
The article Is Novo Nordisk Still an Attractive Investment? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. Simon Erickson owns shares of Novo Nordisk. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.